PVR and neoplasm: Administered into tumors via convection‐enhanced delivery (CED), PVSRIPO activates peripheral tumor microglia through its interaction with CD155 and subsequently recruits antigen‐presenting cells to the site, thereby enhancing the anti‐tumor immune response.